Susan Dorman, MD, Infectious Disease, Baltimore, MD

SusanEDormanMD

Infectious Disease Baltimore, MD

Associate Professor of Medicine, Johns Hopkins University School of Medicine

Are you Dr. Dorman?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

  • Connect with colleagues in the same hospital or clinic
    You already have 74 invites waiting!
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

  • Office

    The Johns Hopkins Hospital
    600 N. Wolfe Street, Sheikh Zayed Tower
    Baltimore, MD 21287
    Phone(410) 955-1725
  • Is this information wrong?

Summary

  • Dr. Susan Dorman, MD is an infectious disease specialist in Baltimore, Maryland. She is currently licensed to practice medicine in Maryland and South Carolina. She is an Associate Professor of Medicine at Johns Hopkins University School of Medicine.

Education & Training

  • National Institutes of Health Clinical Center
    National Institutes of Health Clinical CenterFellowship, Infectious Disease, 1996 - 1999
  • Brigham and Women's Hospital
    Brigham and Women's HospitalResidency, Internal Medicine, 1993 - 1996
  • Duke University School of Medicine
    Duke University School of MedicineClass of 1993

Certifications & Licensure

  • SC State Medical License
    SC State Medical License 2017 - 2021
  • MD State Medical License
    MD State Medical License 1996 - 2018
  • American Board of Internal Medicine Infectious Disease

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Four-Month TB Treatment Matches Six-Month Standard of Care
    Four-Month TB Treatment Matches Six-Month Standard of CareOctober 22nd, 2020
  • Highlights from State and Local Programs
    Highlights from State and Local ProgramsMarch 24th, 2014
  • Will Advances in TB Treatment Outweigh the Covid-19 Pushback?
    Will Advances in TB Treatment Outweigh the Covid-19 Pushback?April 1st, 2021
  • Join now to see all

Grant Support

  • Phase II Study Of Daily Rifapentine For Pulmonary Tuberculosis (Ind 62,611;1/2/0Food And Drug Administration2009–2011
  • Extensively Drug-Resistant Tuberculosis Among GOLD Miners In South AfricaNational Institute Of Allergy And Infectious Diseases2008–2011
  • Rapid Detection Of Mycobacterium TuberculosisNational Institute Of Allergy And Infectious Diseases2003–2007
  • Mycobacterium Tuberculosis Cell Wall Virulence FactorsNational Institute Of Allergy And Infectious Diseases2003–2004